12273-3





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	#10)	Group Art Unit: 1646	RECEIVED
LANGRIDGE, William H.R. et al.)	Examining Attorney: to be assigned	JAN 2 2 2002
Serial No.: 09/771,536)	to be assigned	TECH CENTER 1600/290
Filed: January 29, 2001)		•
For: Transgenic Plant-Based Vaccin	ies)	Pasadena, California	

STATEMENT IN ACCORDANCE WITH 37 CFR 1.821(c) and (e)

United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Sir:

Enclosed with this Statement in the above-identified United States application is a Sequence Listing and a computer readable form of the sequence listing filed herewith in accordance with 37 CFR 1.821(c) and (e).

37 CFR 1.1821(f) - I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted herewith in accordance with 37 CFR 1.1821(c) and (e),

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class in an envelope addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on <u>January 11, 2002</u>

Junals	Porte		
Signature			
ELAINE POR	TER		

09/771,536

respectively, are the same.

No fee is believed due with this Communication. However, the Commissioner is hereby authorized to charge payment of any fees associated with this Communication to Deposit Account No. 19-2090.

Respectfully submitted,

SHELDON & MAK a Professional Corporation

Date: January 11, 2002

David A. Farah, M.D.

Reg. No. 38,134

Sheldon & Mak 225 South Lake Avenue 9th Floor Pasadena, CA 91101 626/796-4000